Skip to Main Content

Waltham-based Adagio Therapeutics announced on Monday that it has raised $336 million in new funding to rapidly advance its Covid-19 antibody treatment, which aims to treat and prevent the disease and all of its known variants.

Last week the Waltham biotech began recruitment for global clinical trial to test the drug’s efficacy as a treatment for high-risk individuals with mild or moderate Covid-19. The goal: to determine whether a single intramuscular dose could prevent hospitalizations and deaths.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.